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Background: Pachymeningitis is a rare disorder characterized
by inﬂammation and thickening of dura mater which may result
in neurological deﬁcits. This condition has largely been reported
in adults, with very few reports in children. The present report
describes a 4 year old boy with pachymeningitis, his course of
illness, and his response to treatment.
Methods & Materials: We report a child with chronic tubercu-
lous pachymeningitis, who presented with clinical manifestations
of meningitis with a compatible cerebrospinal ﬂuid analysis.
Despite signs of progressive neurological involvement, extensive
work-up done to rule out known causes of dural inﬂammation was
negative.
Results: The patient was started empirically on anti-
tuberculous therapy, to which he responded after 2 weeks.
He was discharged on anti-TB medications. He remains well on
follow-up.
Conclusion: We recommend a trial of anti-tuberculous treat-
ment in childrenpresentingwith signsofpachymeningitis inwhom
the cause of chronic meningeal inﬂammation cannot be identiﬁed
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Background: Hospital Associated Infection is a common prob-
lem that affect 1.7 million patients per year in the US with 100 000
deaths at a cost of $45 billion. Half of all HAI occur in intensive
care units (ICU’s) and most are related with invasive devices such
as ventilators, urine and intravascular catheters.
In 2006 SheikhKhalifaMedical City, a 600 bed tertiary care facil-
ity in Abu Dhabi experienced an outbreak of multi drug resistant
Acinetobacter baumanii infections (MDR AB) in our 29 bed adult
ICU. The outbreak involved 4 cases of bacteremia and 1 case of ven-
triculitis. All 5 isolates produced OXA-23 carbapenemases while 4
of the 5 isolates were clonally related.
Since the outbreak we have documented multiple ventilator
associated pneumonia (VAP) cases caused by this notorious organ-
ism with measured VAP rate above the accepted benchmark value.
Methods & Materials: In order to lower infection rates the fol-
lowing Interventions were proposed by a multi-disciplinary task
force involving infection control practitioners, intensivists, micro-
biologists and nurses:
• Screen patients for MDR AB colonization
• Cohort positive MDR AB patients
• Change nursing care matrix where a nurse care only for MDR
negative or positive patients; no cross care allowed.
An interrupted time series study was designed over a 36 month
period to determine the impact of our intervention on outcome
measures (VAP rates, blood stream infections rates, colistin con-
sumption and impact on antibiogram).
Results: Pre-intervention Post-intervention p-value
Total VAP rates (/1000
ventilator days)
4.2 1.4 <0.001
MDR AB VAP rates (/1000
ventilator days)
1.2 0.65 <0.001
MDR AB bacteremias (n) 15 6 <0.005
Colistin consumption
(DDD/1000 days)
73 29 <0.005
% of all respiratory isolates
SENSITIVE to
Piperacillin/Tazobactam
50% 67% <0.005
% of all respiratory isolates
SENSITIVE to: Meropenem
50% 70% <0.005
% of all blood culture isolates
SENSITIVE to
Piperacillin/Tazobactam
65% 75% <0.005
% of all blood culture isolates
SENSITIVE to Meropenem
72% 82% <0.005
Conclusion: MDR AB screening, patient cohorting and nursing
care matrix adjustment have signiﬁcantly lowered total VAP rates,
AB MDR related VAP rates, MDR AB bacteremias and colistin con-
sumption in our adult ICU. Over a study period of 36 months, it
seems that our intervention is effective and sustainable.
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